Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 8-K

PLURISTEM THERAPEUTICS INC

Form 8-K May 09, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 9, 2012

PLURISTEM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Nevada 001-31392 98-0351734

(State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer Identification Number)

MATAM Advanced Technology Park Building No. 20 Haifa, Israel 31905 31905

(Address of principal executive offices)

Registrant's telephone number, including area code: 011 972 74 710 7171

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 8-K

Item 8.01 Other Events.

On May 9, 2012, the registrant issued a press release announcing that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white cells and platelets following the intramuscular injection of the registrant's PLacental eXpanded (PLX) cells.

Edgar Filing: PLURISTEM THERAPEUTICS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

Date: May 9, 2012 By: /s/ Yaky Yanay

Yaky Yanay

Chief Financial Officer